Bavarian Nordic secures US vaccine order

Danish pharmaceutical company Bavarian Nordic received an order from US authorities for smallpox vaccines valued at nearly 1.1 billion Danish kroner, announced in a stock exchange statement on Thursday. The order is for replenishing stocks used during a 2022 outbreak. CEO Paul Chaplin highlighted the vaccine’s key role in US biological preparedness. This contract won’t affect the company’s revenue forecast for the year, which remains at 5-5.3 billion kroner. Although first-quarter 2024 sales fell short of expectations, revenue can be unpredictable and occur in bursts with project successes. Smallpox can cause fever and rash with white blisters. Bavarian has partnered with the US government since 2003 to develop and produce vaccines, ensuring protection for all population groups including those with weakened immune systems. Chaplin commended the US government’s commitment to maintaining a robust defense against public health threats.